Sanofi (SNY) Form 6-K — Jul 30, 2026

Sanofi reported net sales of €22.1 billion for the first half of 2026, an increase of 11.1% reported and 15.7% at constant exchange rates. This growth was primarily driven by Dupixent, which saw sales rise to €9.3 billion, and strong performances from rare disease and oncology portfolios. Despite strong top-line growth, reported net income attributable to equity holders fell to €2.0 billion from €5.8 billion in the prior year. The decline reflects a €1.03 billion impairment charge related to the amlitelimab asset and the comparison against the prior year's gain on the disposal of Opella.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.